EUR 14.6
(0.0%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 10.45 Million GBP | 212.15% |
2022 | 3.35 Million GBP | 90.56% |
2021 | 1.75 Million GBP | 2.39% |
2020 | 1.71 Million GBP | -33.66% |
2019 | 2.58 Million GBP | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 Q4 | 10.45 Million GBP | 0.0% |
2023 FY | 10.45 Million GBP | 212.15% |
2023 Q2 | - GBP | -100.0% |
2022 FY | 3.35 Million GBP | 90.56% |
2022 Q4 | 3.35 Million GBP | 0.0% |
2022 Q2 | - GBP | -100.0% |
2021 FY | 1.75 Million GBP | 2.39% |
2021 Q4 | 1.75 Million GBP | 0.0% |
2021 Q2 | - GBP | -100.0% |
2020 Q4 | 1.71 Million GBP | -42.98% |
2020 FY | 1.71 Million GBP | -33.66% |
2020 Q2 | 3.01 Million GBP | 0.0% |
2019 FY | 2.58 Million GBP | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
BioNTech SE | 219.1 Million EUR | 95.227% |
CureVac N.V. | 41.85 Million EUR | 75.018% |
Biotest Aktiengesellschaft | 689.8 Million EUR | 98.484% |
Biotest Aktiengesellschaft | 689.8 Million EUR | 98.484% |
BRAIN Biotech AG | 4.65 Million EUR | -124.447% |
Formycon AG | 29.48 Million EUR | 64.536% |
Heidelberg Pharma AG | 5.83 Million EUR | -79.323% |
Medigene AG | 2.95 Million EUR | -254.475% |